Skip to Content
Official Responses

The British Association of Dermatologists is invited to comment on a large number of consultation documents each year. These documents are issued by government departments, regulatory bodies and various other organisations around the UK. Please click on any of the "+" symbols in the list below for our most recent and important official responses to the Department of Health, General Medical Council, All Party Parliamentary Group, NICE, MHRA and other professional bodies.

We also keep an archive of all official responses.

Close
NICE Single Technology Appraisal: Adalimumab for treating moderate to severe hidradenitis suppurativa
Close
NICE Single Technology Appraisal: Dabrafenib and trametinib for the treatment of unresectable, advanced or metastatic BRAF-V600 mutation-positive melanoma
Close
NICE Medical Technologies Evaluation: Debrisoft monofilament debridement pad for use in acute or chronic wounds
Close
NICE Accreditation: Public consultation on processes to produce British National Formulary publications
Close
NICE Draft Single Technology Appraisal: Dabrafenib and trametinib for the treatment of unresectable, advanced or metastatic BRAF-V600 mutation-positive melanoma
Close
NICE Interventional Procedures Consultation: Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma
Close
NICE Single Technology Appraisal: Ustekinumab for treating active and progressive psoriatic arthritis
Close
NICE Draft Quality Standards consultation on psoriasis
Close
NICE Public Health Guidance Draft Scope: Vitamin D - implementation of existing guidance to prevent deficiency
Back to top